WHO lamented in 1991: “The endemic countries are unable to proceed with large - scale [snail fever] control programmes because of the high cost of the treatment; the hard currency costs of the drug itself are usually more than the total per capita budget of most African ministries of health. ”
जबकि ये दवाएँ अफ्रीका और दक्षिण अमरीका में, क्षेत्र प्रयोगों में सफल साबित हुई हैं, अनेक देशों के लिए एक मुख्य समस्या रही है क़ीमत । डब्ल्यू. एच.